

Martin Reck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4950861/publications.pdf>

Version: 2024-02-01

37
papers

41,455
citations

159585
30
h-index

345221
36
g-index

38
all docs

38
docs citations

38
times ranked

25949
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Chemotherapy for PD-L1â€“Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2016, 375, 1823-1833.	27.0	7,847
2	Nivolumab versus Docetaxel in Advanced Squamous-Cell Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 123-135.	27.0	7,261
3	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
4	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 2018, 378, 2288-2301.	27.0	2,808
5	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 2018, 378, 2093-2104.	27.0	2,469
6	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2220-2229.	27.0	2,228
7	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 2018, 379, 2342-2350.	27.0	2,150
8	First-Line Nivolumab in Stage IV or Recurrent Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2415-2426.	27.0	2,145
9	Nivolumab plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	27.0	1,866
10	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 2019, 37, 537-546.	1.6	1,144
11	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	10.7	773
12	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and) Tj ETQq0 0 QngBT /Overdock 10 T		
13	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 1505-1517.	1.6	710
14	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 387-401.	10.7	704
15	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%. Journal of Clinical Oncology, 2021, 39, 2339-2349.	1.6	468
16	First-Line Nivolumab Plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology, 2019, 37, 992-1000.	1.6	457
17	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1301-1311.	1.6	445
18	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLCâ€“an Update From the PACIFIC Trial. Journal of Thoracic Oncology, 2021, 16, 860-867.	1.1	323

#	ARTICLE	IF	CITATIONS
19	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	1.6	317
20	First-Line Immunotherapy for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 586-597.	1.6	312
21	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1600-1609.	10.7	282
22	Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 4012-4019.	1.6	276
23	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	1.1	173
24	Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. <i>European Journal of Cancer</i> , 2019, 116, 137-147.	2.8	167
25	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359.	1.6	147
26	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score $\geq 50\%$: Randomized, Double-Blind Phase III KEYNOTE-598 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2327-2338.	1.6	146
27	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	10.7	119
28	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. <i>Journal of Clinical Oncology</i> , 2020, 38, 9501-9501.	1.6	119
29	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2530-2542.	1.6	47
30	Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. <i>Clinical Lung Cancer</i> , 2022, 23, e247-e251.	2.6	47
31	Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. <i>Journal of Clinical Oncology</i> , 2021, 39, 9016-9016.	1.6	25
32	Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. <i>Journal of Clinical Oncology</i> , 2020, 38, 9521-9521.	1.6	17
33	PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS $\geq 50\%$: Data from KEYNOTE-024. <i>Journal of Thoracic Oncology</i> , 2017, 12, S8-S9.	1.1	11
34	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. <i>Journal of Clinical Oncology</i> , 2022, 40, e004273.		10
35	Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non-small-cell lung cancer (NSCLC): LEAP-006. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9118-TPS9118.	1.6	7
36	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. <i>Drugs</i> , 2019, 79, 1937-1945.	10.9	4

#	ARTICLE	IF	CITATIONS
37	ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer, 2022, 166, 112-125.	2.8	4